Members.Bertoni Francesco, MD, Group Leader
Arribas Carmena Alberto, PhD
Cascione Luciano, PhD
Gaudio Eugenio, PhD
Mensah Afua, PhD
Napoli Sara, PhD
Sartori Giulio, PhD
Spriano Filippo, PhD student
Tarantelli Chiara, PhD
Zhang Fangwen, PhD Student
Research areas of our group are the development of new drugs against lymphoma and lymphoma genomics. Accordingly, we apply genomics techniques followed by bioinformatic and functional studies to elucidate the lesions underlying lymphomas and to identify new genes and new potential therapeutic targets. Since the ultimate goal of our research is the improvement of patients outcome, to obtain new and active anti-lymphoma drugs we work in strict collaboration with pharmaceuticals companies in testing novel compounds but we also develop our anti-cancer molecules. The strict connection with the Oncology Institute of Southern Switzerland (IOSI) running clinical trials dedicated to lymphoma patients allows the development of new drugs from pre-clinical to clinical settings. We also perform molecular follow-up studies for national lymphoma clinical trials (SAKK).
- Genetic and epigenetic landscape of marginal zone lymphomas,
- Functional characterization of ETS1 and FLI1 in diffuse large B-cell lymphomas,
- Development of new anti-lymphoma compounds and identification of biomarkers.